KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBT (2016 - 2025)

Historic EBT for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $161.5 million.

  • West Pharmaceutical Services' EBT fell 206.19% to $161.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $600.9 million, marking a year-over-year increase of 263.02%. This contributed to the annual value of $600.9 million for FY2025, which is 263.02% up from last year.
  • Latest data reveals that West Pharmaceutical Services reported EBT of $161.5 million as of Q4 2025, which was down 206.19% from $171.9 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' EBT registered a high of $227.2 million during Q2 2022, and its lowest value of $110.5 million during Q1 2025.
  • For the 5-year period, West Pharmaceutical Services' EBT averaged around $165.7 million, with its median value being $166.5 million (2023).
  • Per our database at Business Quant, West Pharmaceutical Services' EBT soared by 10686.27% in 2021 and then crashed by 3039.48% in 2024.
  • West Pharmaceutical Services' EBT (Quarter) stood at $181.9 million in 2021, then dropped by 29.25% to $128.7 million in 2022, then soared by 30.69% to $168.2 million in 2023, then dropped by 1.96% to $164.9 million in 2024, then dropped by 2.06% to $161.5 million in 2025.
  • Its last three reported values are $161.5 million in Q4 2025, $171.9 million for Q3 2025, and $157.0 million during Q2 2025.